Duane Mitchell
University of Florida · Duke University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Duane Mitchell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:06 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06514898 · Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With MedulloblastomaUniversity of Florida · recruiting · Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma · study chair
- Ph1NCT06254326 · ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult PatientsUniversity of Florida · active not recruiting · Recurrent Oligodendroglioma, Progressive Oligodendroglioma · study chair
- Ph1NCT04837547 · PEACH TRIAL- Precision Medicine and Adoptive Cellular TherapyUniversity of Florida · recruiting · Neuroblastoma, Diffuse Intrinsic Pontine Glioma · study chair
- Ph1NCT03334305 · Adoptive Cellular Therapy in Pediatric Patients With High-grade GliomasUniversity of Florida · terminated · Malignant Glioma, High Grade Glioma · study chair
- Ph2NCT02465268 · Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma MultiformeUniversity of Florida · completed · Glioblastoma Multiforme, Glioblastoma, Malignant Glioma · study chair
- Ph2NCT01326104 · Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal TumorUniversity of Florida · completed · Medulloblastoma, Neuroectodermal Tumor · principal investigator
- Ph1NCT00626015 · Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by SurgeryJohn Sampson · completed · Malignant Neoplasms of Brain · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Addressing tumor heterogeneity in pediatric gliomas with precision adoptive T cell therapyR01CA293376 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2024 to 2026 · $1,731,786 awarded in 2026Same name and institution; not confirmed by an ID
- Automated Cell Processing Platform for Early Research and Development of Cell TherapiesS15OD042560 · OD · UNIVERSITY OF FLORIDA · fiscal years 2026 · $341,822 awarded in 2026Same name and institution; not confirmed by an ID
- University of Florida Health Cancer Center Support GrantP30CA247796 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2026 · $2,134,999 awarded in 2026Same name and institution; not confirmed by an ID
- INSiGHTS - Innovative Next Steps in Gaining Health Improvements Through Translational ScienceUM1TR005128 · NCATS · UNIVERSITY OF FLORIDA · fiscal years 2025 · $5,377,354 awarded in 2025Same name and institution; not confirmed by an ID
- Nanotechnology enabled quantitative imaging of dendritic cell anti-cancer vaccinesR01CA298804 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2025 · $2,628,974 awarded in 2025Same name and institution; not confirmed by an ID
- Together: Transforming and Translating Discovery to Improve HealthUL1TR001427 · NCATS · UNIVERSITY OF FLORIDA · fiscal years 2019 to 2024 · $508,965 awarded in 2024Same name and institution; not confirmed by an ID
- Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in gliomaR01NS108781 · NINDS · UNIVERSITY OF FLORIDA · fiscal years 2018 to 2022 · $378,934 awarded in 2022Same name and institution; not confirmed by an ID
- Efficacy of Dendritic Cell Vaccines Targeting CMV in Glioblastoma (phase 2 DC vaccine)R01CA175517 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2015 to 2020 · $269,745 awarded in 2020Grant number is on one of their registry trials
- Enhancing Adoptive Immunotherapy Targeting Pediatric High-Grade GliomasR01CA195563 · NCI · UNIVERSITY OF FLORIDA · fiscal years 2015 to 2019 · $614,852 awarded in 2019Grant number is on one of their registry trials
- Reversal of CMV-specific Immune Deficits in Patients with GlioblastomaR01NS067037 · NINDS · UNIVERSITY OF FLORIDA · fiscal years 2009 to 2013 · $308,239 awarded in 2013Same name and institution; not confirmed by an ID
- Adoptive Immunotherapy for GBM During Hematopoietic Recovery from TemozolomideR01CA134844 · NCI · DUKE UNIVERSITY · fiscal years 2009 to 2012 · $312,186 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Effect on IL-2R Antibody on Regulatory T-cells in Patients with Malignant GliomasR21CA132891 · NCI · DUKE UNIVERSITY · PI JOHN H. SAMPSON · fiscal years 2008 to 2009Named on NCT00626015
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:06 UTC. The ranking covers the 200 most relevant of 191 PubMed records, and a shared surname and initials can bring in a namesake. All 191 on PubMed
- 650 citationsRCR 14.4
- Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol · 2004515 citationsRCR 9.3
- Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients.Nature · 2015442 citationsRCR 12.5
- 413 citationsRCR 12.2
- 391 citationsRCR 15.0
- Treatment of periodontal disease and the risk of preterm birth.N Engl J Med · 2006385 citationsRCR 12.7
- Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.J Clin Oncol · 2005335 citationsRCR 6.1
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.Neuro Oncol · 2011295 citationsRCR 6.9
- 271 citationsRCR 10.6
- British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.Thorax · 1996257 citationsRCR 9.4